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  SPECTROPHOTOMETRIC DETERMINATION 
OF NICRADIPINE AND ISRADIPINE IN 
PHARMACEUTICAL FORMULATIONS 
A sensitive spectrophotometric method was developed for the determination of 
some 1,4-dihydropyridine compounds namely, nicardipine and isradipine either 
in pure form or in pharmaceutical preparations. The method is based on the 
reduction of nicardipine and isradipine with zinc powder and calcium chloride 
followed by further reduction with sodium pentacyanoaminoferrate (II) to give 
violet and red products having the absorbance maximum at 546 and 539 nm 
with nicardipine and isradipine, respectively. Beer’s law was obeyed over the 
concentration range 8.0–180 µg/ml with the detection limit of 1.67 µg/ml for 
nicardipine and 8.0–110 µg/ml with the detection limit of 1.748 µg/ml for isradi-
pine. The analytical parameters and their effects on the reported methods were 
investigated. The molar absorptivity, quantization limit, standard deviation of 
intercept (Sa), standard deviation of slope (Sb) and standard deviation of the re-
siduals (Sy/x) were calculated. The composition of the result compounds were 
found 1:1 for nicardipine and 1:2 for isradipine by Job’s method and the con-
ditional stability constant (Kf) and the free energy changes (ΔG) were calcula-
ted for compounds formed. The proposed method was applied successfully for 
the determination of nicardipine and isradipine in their dosage forms. The re-
sults obtained were in good agreement with those obtained using the reference 
or official methods. A proposal of the reaction pathway was presented. 
Key words: spectrophotometer; nicardipine; isradipine; pharmaceutical 
preparations. 
 
 
Calcium antagonists block the influx of calcium 
ions through voltage-operated calcium channels loca-
ted in the cell membrane. Among the different groups, 
dihydropyridines is the most numerous and includes 
the largest number of novel compound. They act upon 
the L-type channel, which has a specific dihydropyri-
dine site in its extra cellular surface and bind more 
selectively to vascular calcium channels than to those 
in the myocardium. Newer dihydropyridines exhibit 
greater selectivity, with evidence for a specific vascu-
lar vessel bed binding. Each of these agents is effecti-
ve in the treatment of hypertension and angina pec-
toris [1-3]. 
The therapeutic importance of dihydropyridines 
initiated several methods on its determination, both in 
formulations and in biological fluids. These methods 
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include: spectrofluorometric [4], voltammetric [5-9], am-
perometric [10] thin-layer chromatographic [11], capil-
lary gas chromatographic [12] and high-performance 
liquid chromatographic [13-15]. The visible spectro-
photometric methods are the instrumental methods of 
choice commonly used in industrial laboratories be-
cause of their simplicity, selectivity and sensitivity. In 
the literature, only few spectrophotometric methods 
have been reported for dihydropyridines compounds. 
Derivative spectrophotometric procedures have been 
described for the determination of amlodipine besyl-
ate based on the formation of an oxidative coupling 
product of the drug with 3-methyl-2benzothiazolinone 
hydrazone hydrochloride in the presence of ceric am-
monium sulphate [16]. Another spectrophotometric 
method for the determination of nifedipine depends 
on the reduction of nitro group to hydroxylamino group 
which then reacted with N-methyl-1,4-benzoquinone-
imine to form colored product [17]. A number of other 
extractive spectrophotometric methods [18-21] have 
also been reported in literature for the assay of dihyd-
ropyridines in pharmaceutical formulations. The char-
ge transfer reaction has been used for the determi-S. M. AL-GHANNAM and A. M. AL-OLYAN: SPECTROPHOTOMETRIC DETERMINATION…  CI&CEQ 15 (2) 69−76 (2009) 
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nation of amlodipine besylate with ρ-chloranilic acid in 
1,4-dioxan-chloroform medium[22]. 
Sodium pentacyanoaminoferrate (II) (SCAF) has 
been used to detect aromatic nitro compounds [23]. 
The compounds studied were: nicardipine (NIC), 
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)methyl-2-[me-
thyl(phenyl methyl)amino]-3,5-pyridinedicarboxylic acid 
ethyl ester, and isradipine (ISRA), 4-(4-benzofuraza-
nyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic 
acid methyl 1-methylethyl ester. 
 
Nicardipine 
 
Isradipine 
The aim of this work is the development of a 
simple and sensitive method for the determination of 
NIC and ISRA in the pure and pharmaceutical prepa-
rations. The proposed method is based on the re-
duction of nicardipine and isradipine with zinc powder 
and calcium chloride followed by further reduction 
with sodium pentacyanoaminoferrate (II) to give color 
products. The results obtained were promising. 
EXPERIMENTAL 
Apparatus 
All Absorption spectra were made M501 using 
UV-Visible spectrophotometer (Cambridge, UK) with 
a scanning speed of 200 nm/min, wavelength range 
190-1100 nm and a band width of 2.0 nm, equipped 
with 1 cm quartz cells. 
Materials and reagents 
All chemicals and reagents used were of analy-
tical grade and used without further purification. 
Double distilled de-ionized water was used to prepare 
all solutions. 
Materials 
Nicardipine hydrochloride was obtained from 
Sigma chemical co. (St. Louis, MO, USA). Isradipine 
was gratefully gifted by Novartis Pharma (Basle, Swi-
tzerland). 
Pharmaceutical formulations 
Tablets contained isradipine (Lomir tablets), la-
beled to contain 2.5 mg of isradipine per tablet (No-
vartis Pharma, AG, Basle, Switzerland). Capsules 
contained nicardipine (Pelcard capsules), labeled to 
contain 50 mg of nicardipine per capsule (Global Napi 
Pharmaceuticals, Egypt). 
Standard solutions 
Stock solutions of pure NIC and ISRA were pre–
pared separately by dissolving 0.1 g of NIC and ISRA 
in methanol then completed to 100 ml with the same 
solvent. Working solutions of lower concentrations were 
prepared by the appropriate dilution with methanol. 
Reagents 
Sodium pentacyanoaminoferrate (II) Na3[Fe(CN)5NH3] 
(SCAF) was prepared according to Vogel [24], and used 
as a 0.1% solution, made fresh daily. 
Calcium chloride solution, 10% (w/v), was ob-
tained from (BDH, Poole, England). 
Zinc powder was obtained from (BDH, Poole, 
England). 
General recommended procedures 
Procedure for calibration graphs 
Into a series of 25 ml measuring flasks, accura-
tely measured aliquots of standard NIC or ISRA solu-
tions in the concentration range shown in (Table 1) 
were transferred. A 0.3 g of zinc powder for NIC or 
0.1 g zinc powder for ISRA and 5 ml of calcium chlo-
ride solution were added for each flask. The reaction 
mixture was left to stand for 5 min at room tempera-
ture with occasional shaking. The mixture was filtered 
through a dry filter paper (Whattman No. 42) into 25 
ml measuring flasks. Each residue was washed tho-
roughly with three 2-ml portions of ethanol and wash-
ings passed to the same flask. 5 ml of SCAF solution 
was added to each combined filtrate and washings, 
and the mixture was left to stand for 10 min at room 
temperature. The volume was completed to the mark 
with distilled water. The absorbance was measured at 
546 or 539 nm for NIC or ISRA, respectively. A blank 
reagent without the drug was carried out simultane-
ously. Calibration graphs were constructed by plotting S. M. AL-GHANNAM and A. M. AL-OLYAN: SPECTROPHOTOMETRIC DETERMINATION…  CI&CEQ 15 (2) 69−76 (2009) 
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the absorbance versus the final concentration (μg/ml) 
of the drugs. Alternatively, the regression equations 
were derived. 
Procedure for pharmaceutical formulations 
The contents of twenty tablets (Lomir tablets la-
beled to contain 2.5 mg of isradipine per tablet) or 
contents of ten capsules (Pelcard capsules labeled to 
contain 50 mg of nicardipine per capsule) were crush-
ed, powdered or emptied. An accurate weight equiva-
lent to 25 mg NIC or ISRA was dissolved in 20 ml of 
methanol with shaking for 5.0 min and filtered. The fil-
trate was diluted in a 25 ml measuring flask with me-
thanol. An aliquot of the diluted drug solution was treat-
ed as described. The found content of the tablets or 
capsules were calculated either from the calibration 
graph or the regression equation. 
RESULTS AND DISCUSSION 
Optimization of experimental parameters 
The reduction of NIC or ISRA with the zinc and 
calcium chloride solution and subsequently reacted 
with SCAF in aqueous ethanol, produces a violet or 
red product, respectively, having a broad absorption 
peak with its maximum at 546 nm for NIC and 539 nm 
for ISRA (Figure 1). The various experimental factors 
affecting the development and stability of the reaction 
product were studied and optimized. Such factors were 
changed individually, while others remained constant, 
which include the amount of zinc powder, the concen-
tration of the calcium chloride solution, the concentra-
tion of SCAF solution, time of reaction, the effect of 
the reaction temperature, stability of the product and 
the effect of interferences. 
Table 1. Analytical parameters for the determination of nicardipine and isradipine using the proposed method 
Parameter 
Compound 
Nicardipine Isradipine 
c / μg ml
-1 
8-180 8-110 
Wavelength λmax, nm  546.0  539.0 
Molar absorption coefficient, 10
3 l mol
-1 cm
-1 2.41  2.73 
Linear regression equation  A = 0.005c + 0.002  A = 0.006c + 0.032 
Correlation coefficient, r 0.9960  0.9970 
Detection limit, μg/ml 1.67  1.74 
Quantiation limit, μg/ml 5.58  5.27 
Sy/x×10
3  6.01
  5.62
 
Sa×10
3 2.79  3.16 
Sb×10
5 10.2  5.1 
Kf×10
-3
  104.12 0.3725 
ΔG, kJ/mol  -6.27  -3.51 
 
Figure 1. Absorption spectrum of the reduction product of nicardipine (160 µg/ml) (A) and isradipine (36 µg/ml) (B) with SCAF. S. M. AL-GHANNAM and A. M. AL-OLYAN: SPECTROPHOTOMETRIC DETERMINATION…  CI&CEQ 15 (2) 69−76 (2009) 
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Effect of the amount of zinc powder 
The influence of the amount of zinc powder was 
studied using different amounts of zinc 0.05-0.6 g. It 
was found that the reaction took place starting from 
0.2 g upwards for NIC and hence, 0.3 g was selected 
as the optimum amount. The absorbance remains 
constant by using 0.05-0.1 g of zinc powder for ISRA, 
then the absorbance decreases by increasing the 
amount of zinc and hence, 0.1 g was selected as the 
optimum amount. 
Effect of calcium chloride solution concentration 
The reduction between the studied drugs and 
zinc powder takes place in the presence of calcium 
chloride. Different volumes of CaCl2 solution ranging 
from 1.0-8.0 ml (10% w/v) were tested along with the 
amount of zinc chosen. It was noticed that 1-3 ml of 
10% CaCl2 was necessary without altering the com-
pleteness of reduction of NIC or ISRA. 
Effect of SCAF concentration 
The effect of SCAF was studied by using in-
creasing concentrations of SCAF. It was found that 
100 or 280 μg/ml of SCAF is appropriate for maxi-
mum absorbance intensity for NIC or ISRA, respectti-
vely. Excess concentrations of SCAF (300-400 μg/ml) 
had little effect on the absorbance of ISRA. 
Effect of reaction time 
The reaction of NIC or ISRA and SCAF depends 
on time. Maximum absorbance intensity was obser-
ved after 8.0 min for NIC and 3.0-6.0 min for ISRA, at 
room temperature. 
Effect of reaction temperature 
The reduction of NIC or ISRA was studied at dif-
ferent temperatures (25–100 °C). The values of maxi-
mum absorbance of the reduction product were al-
most constant from 25 to 65 °C for NIC, further tem-
perature decreases the absorbance. For ISRA, it was 
observed that raising the temperature up to 30 °C has 
no effect on the absorbance of the product, whereas 
above 30 °C, the absorbance starts to decay. There-
fore, working at room temperature of about 25 °C was 
recommended in the procedure. 
Stability of the product 
The stability of the reduction product was evalu-
ated and constant absorbance readings were obtain-
ed after more than 5 h of standing at room tempera-
ture without any change in color intensity. 
Stoichiometric relationship 
Job’s method of continuous variation [25] of equi-
molar solutions was employed: 2.7×10
-3 M standard 
solution of drugs and 2.7×10
-3 M  s o l u t i o n  o f  S C A F  
was used. A series solution was prepared in which 
the total volume of drug and reagent was kept at 10 
ml. The absorbance was measured at the optimum 
wavelength. The molar ratio of the reagent (drug: SCAF) 
in the product was determined by the method con-
tinuous variations (Job’s method).The results indicate 
that (1:1) for (NIC:SCAF) and (1:2) for (ISRA:SCAF) 
are formed. The suggested mechanism for the reac-
tion products are given in (Scheme 1). 
 
 
Scheme 1. Proposed pathway of the reduction of NIC and ISRA. S. M. AL-GHANNAM and A. M. AL-OLYAN: SPECTROPHOTOMETRIC DETERMINATION…  CI&CEQ 15 (2) 69−76 (2009) 
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Conditional stability constants (Kf) 
The conditional stability constants (Kf) of the re-
duction products were calculated from continuous va-
riation data using Mollard method [26]. Using this 
equation, the stability constants were found to be as 
shown in Table 1. These values obtained indicate 
very stable reaction products. The standard free ener-
gy changes of production (ΔG) were calculated from 
the association constants (Table 1) by the following 
equation [27]:  
ΔG = - 2.303RTlog Kf 
Where  ΔG is the free energy change of the 
product (kJ mol
-1), R the gas constant (1.987 cal mol
-1 
K
-1), T the temperature in Kelvin (273 + t (°C)), and Kf 
is the association constant of drug-reagent reduction 
products (l mol
-1). The negative values of ΔG point out 
to the spontaneous nature of the reactions. 
Effect of interferences 
In order to evaluate the selectivity of the pro-
posed method for the analysis of pharmaceutical for-
mulations, the effects of the presence of excipients 
and additives which can occur in real samples were 
investigated. It was found that the presence of com-
mon excipients of tablets and capsules such as talc, 
starch, gelatin, glucose, sulfate, acetate, phosphate 
and magnesium stearate did not interfere with the de-
termination of the studied drugs at the levels normally 
found in dosage forms. 
Method validation 
Linearity 
Standard calibration curves were constructed by 
plotting absorbance versus concentration (µg/ml) as 
follows: 
For NIC concentration range (8.0-180 µg/ml): 
A = 0.005c + 0.002,  r = 0.9960 
For ISRA concentration range (8.0-110 µg/ml): 
A = 0.006c + 0.032,  r = 0.9970 
The statistical parameters were given in the reg-
ression equation calculated from the calibration graphs, 
along with the standard deviations of the slope (Sb) 
and the intercept (Sa) on the ordinate and the stan-
dard deviation residuals (Sy/x). 
The linearity of calibration graphs was proved by 
high values of the correlation coefficient (r) and the 
small values of the y-intercepts of the regression 
equations. The apparent molar absorptivities of the 
resulting colored reduction products and relative stan-
dard deviation of response factors for each proposed 
spectrophotometric method were also calculated and 
recorded in Table 1. 
Sensitivity 
The detection limits (LOD) for the proposed me-
thods were calculated using the following equation [28]: 
k
s
LOD
3
=  
where s is the standard deviation of replicate deter-
mination values under the same conditions as for the 
sample analysis in the absence of the analyte, and k 
is the sensitivity, namely the slope of the calibration 
graph. In accordance with the formula, the detection 
limits were found to be 1.67 μg/ml for NIC and 1.74 
μg/ml for ISRA. 
The limits of quantization, LOQ, are defined as 
[28]: 
k
s
LOQ
10
=  
According to this equation, the limits of quan-
tization were found to be 5.58 μg/ml for NIC and 5.27 
μg/ml for ISRA (Table 1). 
Specificity, precision, and accuracy 
The specificity of the reduction reaction and se-
lective determination of NIC and ISRA could be pos-
sible. Percentage relative standard deviation (RSD, 
%) as precision and percentage relative error (Er, %) 
as accuracy of the suggested method was calculated. 
The precision was carried out by three determinations 
at 13 different concentrations in this spectrophotomet-
ric method. The percentage relative error was calcu-
lated using the following equation: 
Added
Added Found
Er
−
=100  
The precision and accuracy results are shown in 
Table 2. These results of accuracy and precision show 
that the proposed method has good repeatability and 
reproducibility. 
Analysis of pharmaceutical formulations 
The proposed method has been successfully 
applied to the determination of NIC and ISRA in pure 
samples. The results obtained were compared with 
those given by the reference RP-HPLC method [29] 
and the official method [30]. The reference method 
[29] adopted for the quantization of nicardipine hydro-
chloride in capsules. The RP-HPLC involved the em-
ployment of µ-Bondapak-C18 column and the mobile 
phase consisting of 80% (v/v) CH3CN and 20% (0.01 
M) sodium acetate buffer adjusted to pH 3.5 with ace-S. M. AL-GHANNAM and A. M. AL-OLYAN: SPECTROPHOTOMETRIC DETERMINATION…  CI&CEQ 15 (2) 69−76 (2009) 
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tic acid, the flow rate was 1.5 ml/min. The chromato-
graphic procedure official method [30] for the determi-
nation of isradipine was carried out using a stainless 
steel column (10 cm×4.6 mm) packed with the statio-
nary phase C  (5 µm) (Brownlee Spheri ODS 5µ is 
suitable), and the mobile phase consisting of a mix-
ture of 125 volumes of  acetonitrile, 270 volumes of 
tetrahydrofuran and 625 volumes of water with a flow 
rate of 1.2 ml per min and a detection wavelength of 
230 nm. 
Statistical analysis [28] of the results obtained 
from both the methods revealed no significant differ-
rence between the performance of the two methods 
regarding accuracy and precision as revealed by Stu-
dent’s t-test and variance ratio, F-test, (Table 2). 
The proposed method was further applied to 
commercial tablets and capsules containing NIC or 
ISRA. The results obtained are shown in Table 3. The 
average percent recoveries were quantitative, indica-
ting good accuracy of the method and the value of 
t-test and F-value revealed no significant difference 
between the performances of the two methods. 
The accuracy and precision (intra-day precision 
or repeatability and inter-day or intermediate preci-
Table 2. Application of the proposed spectrophotometric method for the determination of nicardipine and isradipine in pure forms 
Compound 
Amount added 
μg/ml 
Amount found 
μg/ml 
Recovery
a, %  RSD, %  Er, % 
Amount added 
μg/ml 
Reference and official 
methods
 [29,30]
 
Nicardipine  8 7.97  99.59  0.88  -0.41  0.02  101.60 
12 12.07  100.55  0.73  0.55  0.04  99.75 
16 15.84 98.98  0.33  -1.02  0.08  100.93 
24 24.03  100.14  0.45  0.14  0.10  101.62 
32 31.25 97.64  1.12  -2.36  0.12  99.28 
36 36.33  100.91  0.64  0.91  –  – 
60 60.68  101.14  0.40  1.14  –  – 
80 79.63 99.54  0.77  -0.46  –  – 
100 100.16 100.16  1.35  0.16  –  – 
120 121.21 101.01  0.98  1.01  –  – 
140 140.68 100.49  0.76  0.49  –  – 
160 158.58 99.11  0.81  -0.89  –  – 
180 181.74 100.96  0.95  0.96  –  – 
Mean±SD   100.02±1.02 
 
– 100.64±1.08  (n = 5) 
RSD, %    1.1979  –  – 
F   1.12  (5.14)  –  – 
t   1.14  (2.31)  –  – 
Isradipine  8 8.08  101.03  0.55  1.03  0.02  97.53 
12 12.00  100.00  0.78  0.00  0.04  101.45 
16 16.12  100.77  1.02  0.77  0.06  102.85 
20 19.94 99.69  0.99  -0.31  0.08  96.53 
28 28.39  101.40  0.32  1.40  0.10  98.38 
36 35.92 99.77  0.65  -0.23  0.12  102.55 
50 49.82 99.64  0.44  -0.4  –  – 
60 58.82 98.03  0.71  -2.0  –  – 
70 68.82 98.31  0.39  -1.7  –  – 
80 80.62  100.78  0.86  0.8  –  – 
90 88.62 98.47  1.22  -1.5  –  – 
100 100.42 100.42  0.89  0.4  –  – 
110 108.02 98.20  0.40  -1.8  –  – 
Mean±SD 
 
99.73±1.16 
 
– 99.88±2.74  (n = 6) 
RSD, %  1.1631  –  – 
F
b  5.60 (5.79)  –  – 
t
b  0.31 (2.37)  –  – 
aThe average of three trials; 
bthe figures in parentheses are the theoretical values of t and F values at 95% confidence limit S. M. AL-GHANNAM and A. M. AL-OLYAN: SPECTROPHOTOMETRIC DETERMINATION…  CI&CEQ 15 (2) 69−76 (2009) 
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sion) of this method, evaluated by assaying three dif-
ferent concentrations of NIC and ISRA, are summa-
rized in Table 4. The differences of the mean value 
measured from the concentration prepared, expres-
sed in percentages, were only -0.21, 0.13 and –3.88% 
at 40, 60 and 80 µg/ml of NIC and 0.34, 1.23 and 
–3.41 µg/ml at 40, 60 and 80 µg/ml of ISRA, which 
confirmed the accuracy of the method. The range of per-
centage of relative standard deviation (RSD) was 1.9–
-3.6% and 2.7–3.7% for NIC and 1.6–5.1% and 1.6–4.6% 
for ISRA for within-day and between-day analyses, 
respectively. The RSD values obtained allow us to con-
clude that the method has an acceptable precision. 
A systematic study of the effects of excipients 
was performed by adding a known amount of the ex-
cipient to 80 µg/ml NIC or ISRA, filtering off the inso-
luble excipient, washing the residue, diluting in a volu-
metric flask and analyzing following the recommend-
ed procedure. The results revealed that no significant 
interference was observed from excipients, such as 
starch, talc, gelatin, glucose and magnesium stearate. 
CONCLUSION 
The present method has the advantages of high 
sensitivity (detection limit = 1.67 for NIC and 1.74 
µg/ml for ISRA). On the other hand, the proposed me-
thod is low cost, selective, accurate and precise (in-
tra-day and inter-day precision) as indicated by the 
good results of the drugs. Furthermore, the proposed 
method does not require the elaboration of the proce-
dures which is usually associated with chromatogra-
Table 3. Application of the proposed spectrophotometric method for the determination of nicardipine and isradipine in their pharma-
ceutical formulations 
Preparation 
Amount taken 
μg/ml 
Amount found 
μg/ml 
Recovery
a, %
  Amount added 
μg/ml 
Reference and official 
methods [30,31] 
Pelcard capsules 
labeled to contain 50 mg 
of nicerdipine per 
capsule
b 
32 31.62 98.84  0.04  101.12 
40 39.96 99.91  0.10  100.52 
48 48.11  100.23  0.12  100.32 
56 55.52 99.14  –  – 
64 64.22  100.35  –  – 
72 71.26 98.97  –  – 
80 79.04 98.80  –  – 
Mean±SD   99.46±0.68    100.65±0.42 
F   2.62  (8.89)     
t   0.20  (2.31)     
Lomir tablets labeled to 
contain 2.5 mg of 
isradipine per tablet
c 
16 15.87  99.19  0.04  99.84 
24 24.02  100.08  0.10  101.11 
32 31.79  99.36  0.12  101.34 
40 39.94  99.86  –  – 
60 59.39  98.98  –  – 
80 79.20  99.00  –  – 
Mean±SD   99.41±0.46    100.76±0.80 
F   3.02  (4.76)     
t   0.38  (2.37)     
aThe average of three trials; 
bGlobal Napi Pharmaceuticals, Egypt; 
cNovartis Pharma, AG, Basle, Switzerland 
Table 4. Precision of the method for the determination of NIC and ISRA in pharmaceutical formulations, expressed as relative standard 
deviation (RSD) 
Compound  Concentration, µg/mL  Accuracy, %  Intra-day precision RSD, %  Inter-day precision RSD, %
Nicardipine 40  -0.21  3.6  2.7 
 60  0.13  1.9  3.7 
 80  -3.88  2.7  3.5 
Isradipine 40  0.34  1.6  1.9 
 60  1.23  3.5  4.6 
 80  -3.41  5.1  2.8 S. M. AL-GHANNAM and A. M. AL-OLYAN: SPECTROPHOTOMETRIC DETERMINATION…  CI&CEQ 15 (2) 69−76 (2009) 
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phic methods. The disadvantage of this method is the 
tediousness of filtration. The proposed method could 
be applied successfully for the determination of nicer-
dipine and isradipine in pure forms, as well as dosage 
forms, with no interferences from tablets or capsules 
excipients. 
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